SCHEMBL25848781

SCHEMBL25848781

CNS(=O)(=O)c1ccc(C(=O)NCc2ccc(C)c(F)c2)s1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.41
MMP13 P45452 1/20 0.40
CHRM4 P08173 3/20 0.40
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
AKT3 Q9Y243 1/20 0.39
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
MAOB P27338 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
HPGDS O60760 1/20 0.38
POLB P06746 1/20 0.37
SCD O00767 1/20 0.37
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25848927 0.88 KDM4E (0.42) KMT2ACHRM4NPC1ALDH1A1RAB9A
SCHEMBL25848775 0.83 MEN1 (0.52) KMT2AALDH1A1SMN1; SMN2MAOBKDM4E
SCHEMBL25848785 0.81 MMP13 (0.49) KMT2AMMP13ALDH1A1MAOBKDM4E
SCHEMBL25848928 0.80 CA1 (0.46) KMT2ACHRM4SMN1; SMN2AKT3HDAC3
SCHEMBL25848884 0.80 CCR1 (0.47) KMT2ACHRM4NPC1ALDH1A1RAB9A
SCHEMBL25848773 0.80 P2RX7 (0.41) KMT2ACHRM4SMN1; SMN2HDAC1HDAC6
SCHEMBL25849324 0.79 PPARA (0.49) CHRM4HDAC3HDAC4HDAC1HDAC6
SCHEMBL25261026 0.78 DYRK1A (0.50) KMT2ANPC1AKT3MAOBMEN1
SCHEMBL30393532 0.78 DYRK1A (0.50) KMT2ANPC1AKT3MAOBMEN1
SCHEMBL25848828 0.78 EPHX2 (0.53) KMT2ANPC1RAB9AHDAC3HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE PRAXIS PRECISION MEDICINES, INC. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219921-A1 KCNT1 INHIBITORS AND METHODS OF USE KCNT1, KCNT2, KCNQ2 KMT2A 232/4885MMP13 4623/4885CHRM4 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.